Target intelligence / Profile preview

Ribosomal protein L13a pseudogene 9 (RPL13AP9)

Target: RPL13AP9
Molecular classification: Other (Pseudogene)

Overview

RPL13AP9, or ribosomal protein L13a pseudogene 9, is a processed pseudogene—meaning it is a segment of DNA that resembles the ribosomal protein L13a gene (RPL13A) but is generally non-functional and does not encode a protein product[5]. It has no direct biological or therapeutic role. Its parent gene, RPL13A, is a structural component of the ribosomal 60S subunit and participates in protein synthesis and inflammatory gene regulation, but these functions are not attributed to the pseudogene variant[1][4][5][7].

Other names: RPL13A_1_58

Mechanism of action

None. Mechanism of action is not applicable, as no drugs are known to target this pseudogene[5].

Biological functions

There are no known direct biological functions for RPL13AP9, as pseudogenes typically do not encode an active protein product. Its sequence is similar to the parent gene, but it is thought to lack function[5].

Disease associations

No direct disease associations are described for RPL13AP9, consistent with the general status of pseudogenes. The parent gene (RPL13A) has some links to disease, but not the pseudogene[5][7].

Safety considerations

None reported. As a non-functional pseudogene, there are no known safety concerns or therapeutic challenges[5].

Interacting drugs

None. No drugs are reported to interact with RPL13AP9, nor is there any evidence it is druggable[5][7].

Biomarkers

None. RPL13AP9 is not reported as a biomarker for patient selection or efficacy monitoring[5][7].

Beyond the preview

Go deeper on Ribosomal protein L13a pseudogene 9 (RPL13AP9).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribosomal protein L13a pseudogene 9 (RPL13AP9).

Explore the full profile